Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012

NCT02639065 is registered in ClinicalTrials.gov with Shadia Jalal, MD as lead sponsor.

NCT NCT02639065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02639065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Lead sponsor
Shadia Jalal, MD
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2016
Completion date
June 9, 2021
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer